Role of Noninvasive Tests (13C-Urea Breath Test and Stool Antigen Test) as Additional Tools in Diagnosis of Helicobacter Pylori Infection in Patients with Atrophic Body Gastritis

Background. Detection of Helicobacter pylori infection in atrophic body gastritis (ABG) is difficult, as during progression of body atrophy, H. pylori disappears. Aim. To increase the diagnostic yield of detection of active H. pylori infection in atrophic body gastritis patients by using noninvasive tests such as C-13-Urea Breath Test (C-13-UBT) and H. pylori stool antigen test (HpSA) would be useful. Patients. 27 consecutive patients with newly-diagnosed atrophic body gastritis (19F/7M, age 27-73 years). Methods. Gastroscopy with biopsies (antrum n = 3, body n = 3) and histology according to updated Sydney system, H. pylori IgG serology, C-13-UBT, and HpSA. Results. All tests used in the diagnosis of H. pylori infection were in agreement in 9/27 atrophic body gastritis patients (33.3%), being all positive in four (14.8%) and all negative in five patients (18.5%). Ten of the 27 (37%) patients were Giemsa stain-positive and serology-positive (group I). Seventeen of the 27 (63%) patients were Giemsa stain-negative: 5/17 with positive serology (group II) and 12/17 with negative serology (group III). In group I, 5/10 (50%) were C-13-UBT positive and 4/10 (40%) HpSA positive. In group II, two patients were C-13-UBT positive, but all were HpSA negative. Also in group III, all patients were HpSA negative, but one had a positive C-13-UBT. Conclusions. In atrophic body gastritis patients, neither C-13-UBT nor HpSA per se add useful information regarding active H. pylori infection, but these noninvasive tests may be important in combination with histology and serology to define the H. pylori status in some atrophic body gastritis patients.

Background. Detection of Helicobacter pylori infection in atrophic body gastritis (ABG) is difficult, as during progression of body atrophy, H. pylori disappears. Aim. To increase the diagnostic yield of detection of active H. pylori infection in atrophic body gastritis patients by using noninvasive tests such as 13C-Urea Breath Test (13C-UBT) and H. pylori stool antigen test (HpSA) would be useful. Patients. 27 consecutive patients with newly-diagnosed atrophic body gastritis (19F/7M, age 27-73 years). Methods. Gastroscopy with biopsies (antrum n = 3, body n = 3) and histology according to updated Sydney system, H. pylori IgG serology, 13C-UBT, and HpSA. Results. All tests used in the diagnosis of H. pylori infection were in agreement in 9/27 atrophic body gastritis patients (33.3%), being all positive in four (14.8%) and all negative in five patients (18.5%). Ten of the 27 (37%) patients were Giemsa stain-positive and serology-positive (group I). Seventeen of the 27 (63%) patients were Giemsa stain-negative: 5/17 with positive serology (group II) and 12/17 with negative serology (group III). In group I, 5/10 (50%) were 13C-UBT positive and 4/10 (40%) HpSA positive. In group II, two patients were 13C-UBT positive, but all were HpSA negative. Also in group III, all patients were HpSA negative, but one had a positive 13C-UBT. Conclusions. In atrophic body gastritis patients, neither 13C-UBT nor HpSA per se add useful information regarding active H. pylori infection, but these noninvasive tests may be important in combination with histology and serology to define the H. pylori status in some atrophic body gastritis patients.